Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
细胞生物学 囊泡 肿瘤 内分泌与代谢疾病
/
细胞培养
细胞凋亡 帕金森与阿尔茨海默症 肿瘤生长增殖和凋亡 细胞死亡 乳腺癌 衰老 宫颈癌
/
类器官培养添加剂
凋亡 Bcl-2
/ Navitoclax

Navitoclax {[allProObj[0].p_purity_real_show]}

货号：A204180 同义名： ABT-263; A-855071

Navitoclax (ABT-263) 是一种口服有效的 Bcl-2 抑制剂，可与多种 Bcl-2 家族蛋白结合，Ki 值小于 1 nM。

Navitoclax 化学结构 CAS号：923564-51-6
Navitoclax 化学结构
CAS号：923564-51-6
Navitoclax 3D分子结构
CAS号：923564-51-6
Navitoclax 化学结构 CAS号：923564-51-6
Navitoclax 3D分子结构 CAS号：923564-51-6
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Navitoclax 纯度/质量文件 产品仅供科研

货号：A204180 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 Bax ↓ Bcl-2 ↓ Bcl-B ↓ Bcl-w ↓ Bcl-xL ↓ Bfl-1 ↓ Mcl-1 ↓ 其他靶点 纯度
BTSA1 ✔ 99%+
HA14-1 +

Bcl-2, IC50: 9 μM

 		98%
Venetoclax ++++

Bcl-2, Ki: <0.01 nM

 		99%
Navitoclax 99%+
Obatoclax Mesylate +++

Bcl-2, Ki: 0.22 μM

 		99%
ABT-737 +++

Bcl-2, EC50: 30.3 nM

 		+

Bcl-B, EC50: 1.82 μM

 		+++

Bcl-w, EC50: 197.8 nM

 		+++

Bcl-xL, EC50: 78.7 nM

 		99%+
Gambogic Acid +

Bfl-1, IC50: 1.06 μM

Bcl-2, IC50: 1.21 μM

 		++

Bcl-B, IC50: 0.66 μM

 		++++

Bcl-w, IC50: 0.02 μM

 		+

Bcl-xL, IC50: 1.47 μM

 		+

Bfl-1, IC50: 1.06 μM

 		++

Mcl-1, IC50: 0.79 μM

 		Caspase 99% HPLC
BH3I-1 +

BH3-Bcl-xL interaction, Ki: 2.4 μM

 		99%
A-1331852 ++++

Bcl-xL, Ki: <0.01 nM

 		99%+
A-1210477 ++++

MCL-1, IC50: 26.2 nM

 		99%+
Maritoclax ✔ 97%
TW-37 +++

Bcl-2, Ki: 0.29 μM

 		+

Bcl-xL, Ki: 1.11 μM

 		+++

Mcl-1, Ki: 0.26 μM

 		98%
UMI-77 ++

Mcl-1, Ki: 490 nM

 		97%
(R)-(-)-Gossypol acetic acid ++

Bcl-2, Ki: 0.32 μM

 		++

Bcl-xL, Ki: 0.48 μM

 		+++

Mcl-1, Ki: 0.18 μM

 		99%
Sabutoclax ++

Bfl-1, IC50: 0.62 μM

Bcl-2, IC50: 0.32 μM

 		++

Bcl-xL, IC50: 0.31 μM

 		++

Bfl-1, IC50: 0.62 μM

 		+++

Mcl-1, IC50: 0.20 μM

 		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Navitoclax 生物活性

靶点

  • Bcl-xL

    Bcl-xL, Ki:<=0.5 nM

  • Bcl-w

    Bcl-w, Ki:<=1 nM

  • Bcl-2

    Bcl-2, Ki:<=1 nM
描述 The B-cell lymphoma 2 (Bcl-2) family of proteins is composed of both antiapoptotic members, such as Bcl-2, Bcl-xL as well as Bcl-w, and proapoptotic members. Up-regulation of the pro-survival Bcl-2 family proteins is one of the primary means for cancer cells to evade apoptosis. ABT-263, advanced based on ABT-737, is a potent and orally bioavailable Bcl-2 family inhibitor (Bcl-xL Ki≤0.5nM,Bcl-2 Ki≤1nM,Bcl-w Ki≤1nM, FPA assay; Bcl-xL Ki=0.4nM, TR-FRET assay; Mcl-1 IC50=550±40nM, A1 IC50=354±63nM,reported). It can disrupt Bcl-xL/Bcl-xS interaction, as well as activates Bax and cytochrome c (Cyto c) release. ABT-263 exhibited single-agent activity in SCLC and hematologic malignancies but not in the majority of other tumor types. Oral dosing of ABT-263 results in the regression of SCLC and ALL xenograft tumors in vivo. Also it enhances the activity of chemotherapeutic agents[1]. The clinical trials of ABT-263 on relapsed/refractory CLL, platinum-resistant, refractory ovarian cancer, etc. are undergoing[2].
作用机制 ABT-263 directly binds Bcl-2 as well as Bcl-xL and blocks their ability to bind to BIM.[3]

Navitoclax 细胞实验

Cell Line
Concentration Treated Time Description References
H1975 cells 500 nM 48 h To assess the effect of RBM10 reconstitution on EGFR inhibitor-induced apoptosis, results showed that RBM10 reconstitution increased PARP cleavage and caspase 3/7 activity. J Clin Invest. 2022 Jul 1;132(13):e145099.
A014 cells 500 nM 48 h To assess the effect of RBM10 reconstitution on EGFR inhibitor-induced apoptosis, results showed that RBM10 reconstitution increased PARP cleavage and caspase 3/7 activity. J Clin Invest. 2022 Jul 1;132(13):e145099.
PC-9 cells 500 nM 48-72 h To assess the effect of RBM10 knockdown on EGFR inhibitor-induced apoptosis, results showed that RBM10 KD decreased PARP cleavage and caspase 3/7 activity. J Clin Invest. 2022 Jul 1;132(13):e145099.
H3255 cells 500 nM 48-72 h To assess the effect of RBM10 knockdown on EGFR inhibitor-induced apoptosis, results showed that RBM10 KD decreased PARP cleavage and caspase 3/7 activity. J Clin Invest. 2022 Jul 1;132(13):e145099.
MPM cells 1 µM 18-24 h To evaluate the apoptotic priming effect of Navitoclax in combination with AZD8055 on MPM cells, results showed that the combination significantly enhanced apoptosis. Nat Commun. 2023 May 20;14(1):2897.
de-iniDCs 1, 5, 10 μM overnight To evaluate the effect of Navitoclax on DC antigen presentation, results showed that Navitoclax enhanced the antigen presentation capability of DCs. Cancer Discov. 2023 Nov 1;13(11):2448-2469.
liv7k oral cancer cell line 10 µM 72 h To test the growth inhibition effect of drugs under hypoxic and normoxic conditions, results showed that drugs with high cSL-scores exhibited stronger drug response in each condition separately. Nat Commun. 2018 Jun 29;9(1):2546.
MDA-MB-231 cells 10 µM 3 days To evaluate the effect of Navitoclax retreatment, it was found that cells remained sensitive to the drug upon retreatment. NPJ Breast Cancer. 2021 May 26;7(1):60.
MDA-MB-231 cells 10 µM 3 days To evaluate the cytotoxic effect of Navitoclax on MDA-MB-231 cells, it was found that cells were highly sensitive to 72 h treatment but fully recovered after 10 days in drug-free media. NPJ Breast Cancer. 2021 May 26;7(1):60.

Navitoclax 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice U87MG IDH1-R132H orthotopic glioblastoma xenograft model Intraperitoneal 100 mg/kg Three times per week, continuous treatment ABT263 treatment significantly prolonged the survival of mice with IDH1-mutant glioblastoma. Nat Commun. 2017 Oct 20;8(1):1067.
Mice Sf3b1 K700E conditional knock-in mice Oral gavage 25 mg/kg 5 days per week for two weeks Test the combination effect of Navitoclax with Eltanexor, showing preferential sensitivity for SF3B1 mutant cells without excessive toxicity. Leukemia. 2024 Sep;38(9):1894-1905.
Mice H1975 subcutaneous xenografts Oral 50 mg/kg Daily for 14 days To evaluate the therapeutic effect of Navitoclax and Osimertinib combination therapy on RBM10-deficient EGFR-mutant tumors, results showed that the combination significantly increased tumor apoptosis. J Clin Invest. 2022 Jul 1;132(13):e145099.
Mice TNBC-PDX model Oral 100 mg/kg Once daily for 21 days To evaluate the tumor growth inhibitory effect of Navitoclax in combination with Metformin in TNBC-PDX model mice, results showed that the combination significantly inhibited tumor growth and extended survival. Nat Commun. 2019 Feb 6;10(1):620.
Mice MPM PDX model Oral 100 mg/kg Once daily for 21 days To evaluate the efficacy of Navitoclax in combination with AZD8055 in the MPM PDX model, results showed that the combination significantly reduced tumor volume and increased mouse survival. Nat Commun. 2023 May 20;14(1):2897.
Mice Orthotopic MCA205 fibrosarcoma model Intraperitoneal injection 50 mg/kg Day 0 and day 2 To evaluate the activation of cDC1 cells by Navitoclax, results showed that Navitoclax significantly upregulated the activation markers of cDC1 cells. Cancer Discov. 2023 Nov 1;13(11):2448-2469.

Navitoclax 动物研究

Dose Mice: min = 50 mg/kg[4], max = 100 mg/kg[5]
Administration p.o.

Navitoclax 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01423539 Diffuse Large B-Cell Lymphoma Phase 2 Withdrawn(The NAVIGATE study h... 展开 >>as been terminated due to non-safety related reasons.) 收起 << February 2014 United States, California ... 展开 >> Fountain Valley, California, United States, 92708 United States, Florida Hudson, Florida, United States, 34667 United States, Georgia Lawrenceville, Georgia, United States, 30045 United States, Illinois Centralia, Illinois, United States, 62801 Harvey, Illinois, United States, 60426 United States, Indiana Terre Haute, Indiana, United States, 47802 United States, Kentucky Hazard, Kentucky, United States, 41701 Paducah, Kentucky, United States, 42003 United States, Maryland Rockville, Maryland, United States, 20850 United States, Missouri Jefferson City, Missouri, United States, 65109 United States, Montana Great Falls, Montana, United States, 59405 United States, Ohio Newark, Ohio, United States, 43055 United States, Tennessee Nashville, Tennessee, United States, 37203 收起 <<
NCT01053520 Healthy Female Subjects Phase 1 Completed - United States, Illinois ... 展开 >> Site Reference ID/Investigator# 23602 Waukegan, Illinois, United States, 60085 收起 <<
NCT01989585 BRAF V600E Mutation Present ... 展开 >> BRAF V600K Mutation Present Metastatic Melanoma Solid Neoplasm Stage III Cutaneous Melanoma AJCC v7 Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 收起 << Phase 1 Phase 2 Recruiting - United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Suspended Sacramento, California, United States, 95817 United States, Massachusetts Massachusetts General Hospital Cancer Center Withdrawn Boston, Massachusetts, United States, 02114 United States, Missouri Siteman Cancer Center at West County Hospital Suspended Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Suspended Saint Louis, Missouri, United States, 63110 Siteman Cancer Center-South County Suspended Saint Louis, Missouri, United States, 63129 Siteman Cancer Center at Christian Hospital Suspended Saint Louis, Missouri, United States, 63136 Siteman Cancer Center at Saint Peters Hospital Suspended Saint Peters, Missouri, United States, 63376 United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact    732-235-8675       Principal Investigator: Janice M. Mehnert          United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact    888-275-3853       Principal Investigator: James L. Abbruzzese          United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu    Principal Investigator: Kari L. Kendra          United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact    877-312-3961       Principal Investigator: Michael A. Davies 收起 <<

Navitoclax 参考文献

[1]Tse C, Shoemaker AR, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008 May 1;68(9):3421-8.

[2]Levy MA, Claxton DF, et al. Therapeutic inhibition of BCL-2 and related family members. Expert Opin Investig Drugs. 2017 Mar;26(3):293-301.

[3]Del Gaizo Moore V, Brown JR, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007 Jan;117(1):112-21.

[4]Chen Q, Song S, et al. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. 2015 Sep 22;6(28):25883-96.

[5]Ackler S, Xiao Y, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008 Oct;7(10):3265-74.

Navitoclax 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.03mL

0.21mL

0.10mL

5.13mL

1.03mL

0.51mL

10.26mL

2.05mL

1.03mL

Navitoclax 技术信息

CAS号923564-51-6
分子式C47H55ClF3N5O6S3
分子量 974.61
SMILES Code O=C(NS(=O)(C1=CC=C(N[C@H](CCN2CCOCC2)CSC3=CC=CC=C3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4
MDL No. MFCD12756219
别名 ABT-263; A-855071
运输蓝冰
InChI Key JLYAXFNOILIKPP-KXQOOQHDSA-N
Pubchem ID 24978538
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, sealed in dry, 2-8°C
溶解方案

DMSO: 80 mg/mL(82.08 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

DMF: 100 mg/mL(102.6 mM)

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二
方案 三
方案 四

Tags: Navitoclax | 923564-51-6 | ABT-263 | ABT263 | ABT 263 | Bcl-2 Inhibitor | Apoptosis | Bcl-2 Family | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Navitoclax 纯度/质量文件 | Navitoclax 亚型比较 | Navitoclax 生物活性 | Navitoclax 动物研究 | Navitoclax 临床数据 | Navitoclax 参考文献 | Navitoclax 实验方案 | Navitoclax 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z